New York, June 17, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the publication of the report “Cardiovascular Devices Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Device; Application, and End User” – https:/ /www .reportlinker.com/p06279426/?utm_source=GNW
However, the high cost of products and procedures is expected to limit the market growth over the forecast period. Cardiovascular disease (CVD) is likely to remain the leading cause of morbidity and mortality worldwide. Cardiovascular diseases are disorders of the heart and blood vessels and lead to several medical conditions, such as cerebrovascular disease, coronary heart disease, and rheumatic heart disease. Some of the major lifestyle factors that lead to cardiovascular disease and difficulties are smoking, poor diet, and physical inactivity, which increases the risk of heart attacks and strokes. .
Company benchmarking assesses and categorizes the cardiovascular devices market based on product portfolio (product satisfaction, product features and availability), recent market developments (merger and acquisition, new product launch and enhancement , investment and financing, award, agreement, collaboration, & partnership, recognition and expansion) and a geographic presence that helps companies make better decisions and understand the competitive landscape. The report thoroughly explores recent significant developments by leading vendors and innovation profiles in the global Cardiovascular Devices market including Boston Scientific Corporation; Medtronic; GE Healthcare; Koninklijke Philips NV; Siemens Healthineers; Abbott; Johnson and Johnson Services, Inc.; B. Braun Melsungen; comics; and Edwards Lifesciences Corporation.
The key company that launches a distinct growth strategy will have a strong growth potential of the global cardiovascular devices market. The data above indicates recent development activities and the presence of strong companies in their respective fields.
Market-competitive growth strategies help the vendor define an alignment or match between its capabilities and opportunities for future growth prospects. This represents an ongoing merger and acquisition strategy, geographic expansion, research and development, and an optimal or advantageous fit to adopt a new product launch. strategies for expansion and business growth over the forecast period.
This chart provides the depth and breadth of vendor knowledge and one of the key understandings while developing the global Cardiovascular Devices market penetration strategies.
• Abbott announced its intention to acquire Cephea Valve Technologies, Inc. The acquisition is likely to strengthen Abbott’s structural core portfolio.
• Boston Scientific launched the Resonate line of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring HeartLogic heart failure diagnostics. The new devices feature SmartCRT technology and EnduraLife battery technology to improve patient management through personalized care.
Thus, start-ups are contributing significantly to the growth of the cardiovascular devices market.
Based on the device, the global cardiovascular devices market is segmented into electrocardiography (ECG), pacemaker, stent, defibrillator, cardiac catheter, guidewire, heart valve, event monitor, and others. In 2021, the event monitor segment held the largest market share.
However, the electrocardiography (ECG) segment of the cardiovascular devices market is also expected to grow at the highest CAGR of 8.0% during the period 2021-2028. On the basis of application, the cardiovascular devices market is segmented into coronary heart disease, sudden cardiac arrest, stroke, cerebrovascular heart disease, and others. In 2021, the coronary heart disease segment held the largest market share. However, the stroke segment is expected to grow at the highest rate during the forecast period owing to the increase in aneurysms among patients. Based on end-user, the cardiovascular devices market is segmented into hospitals, cardiac centers, and outpatient centers. In 2021, the hospital segment held the largest market share. Furthermore, the hospital segment is also expected to grow at the highest rate in the coming years owing to its advantages.
Various organic and inorganic strategies are adopted by companies operating in the cardiovascular devices market. Organic strategies primarily include product launches and product endorsements.
The inorganic growth strategies observed in the market are acquisitions, collaborations, and partnerships. These growth strategies have enabled players in the cardiovascular devices market to expand their businesses, improve their geographical presence, and contribute to the overall market growth.
Additionally, growth strategies such as acquisitions and partnerships have helped strengthen their customer base and expand their product portfolios. Some of the significant developments by the major players in the cardiovascular devices market are listed below.
In January 2021, Medtronic plc announced the launch of its MyCareLink Heartmobile app to support the world’s first and only pacemaker portfolio that can communicate directly with patients’ smartphones and tablets. It is compatible with pacemakers with Medtronic BlueSync technology.
The MyCareLink Heart mobile app is designed to securely and wirelessly send device data to the Medtronic CareLink network via smart technology, eliminating the need for a dedicated bedside monitor or other monitoring hardware from a distance.
In June 2021, Abbott announced the US launch of Jot Dx, the company’s latest insertable cardiac monitor (ICM). Jot Dx ICM is supported by SyncUP, a personalized service that provides one-on-one training and education to help patients connect and stay connected to their ICM.
In September 2021, Abbott announced its intention to acquire Cephea Valve Technologies, Inc. The acquisition is expected to strengthen Abbott’s structural core portfolio.
In January 2022, Medtronic announced that it would acquire Affera, a developer of cardiac mapping and ablation technologies. The company expects the transaction to close in the first half of 2023.
In February 2022, Abbott announced that the U.S. Food and Drug Administration (FDA) had approved an expanded indication for the company’s CardioMEMS HF System to support the care of more people with ‘heart failure. The sensor provides an early warning system to help doctors protect against worsening heart failure.
Read the full report: https://www.reportlinker.com/p06279426/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.